AKRO News and Press, Akero Therapeutics Inc. From 09/13/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday! News moving stocks this morning include clinical trial updates, earnings reports...

Akero Therapeutics ( NASDAQ: AKRO ) said its drug efruxifermin (EFX) improved liver fibrosis without the worsening of liver disease, meeting the main goal of a Phase 2b study. The trial, dubbed HARMONY evaluated two dose levels, 50mg in 34 people and 28mg ...

50mg (41%) and 28mg (39%) groups demonstrated ≥1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution without worsening of fibrosis, three to five times the placebo rate (15%) ...

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor conference on Tuesday...

33% improved by one fibrosis stage without worsening of NASH; 25% of patients treated with efruxifermin showed NASH resolution Consistent with the results for the pre-cirrhotic population (F1-F3), patients with cirrhosis also had improved markers of liver injury, glucose metabolis...

ETNB stock has remained depressed for a long time. Not even solid SHTG data could change that. 89bio's NASH data next year may help. I covered 89bio ( ETNB ) in early 2021, and the stock is down 75% since then, which gives me a reason to take another look at this com...

Akero Therapeutics press release ( NASDAQ: AKRO ): Q2 GAAP EPS of -$0.77 beats by $0.10 . The company believes that its cash, cash equivalents and marketable securities of $180.73M, plus cash from the Hercules facility (if fully drawn), will be sufficient to fund its c...

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter fin...

SOUTH SAN FRANCISCO, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced the presentation ...

Gainers: Electric Last Mile Solutions (ELMS) +195%. Advent Technologies Holdings (ADN) +185%. Sidus Space (SIDU) +60%. Pennsylvania Real Estate Investment (PEI) +39%. Vivakor (VIVK) +32%. Akero (AKRO) +24%. Revlon (REV) +23%. Zhong Yang Financial Group (TOP) +22%. Decisionpoint Systems (DPSI)...